Overview

A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

Status:
Completed

Trial end date:
2016-01-27

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the pharmacokinetic interactions between simeprevir and ledipasvir in a treatment regimen consisting of simeprevir (SMV), sofosbuvir (SOF), and ledipasvir (LDV) in treatment-naive participants with chronic hepatitis C virus (HCV) genotype 1 infection.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Sciences Ireland UC

Treatments:

Ledipasvir
Simeprevir
Sofosbuvir